Investment Rating - The investment rating for the company is "Outperform the Market" [5][21]. Core Insights - The overseas sales of Furazolidone continue to grow, with a positive revenue guidance for 2026. The total market sales for the company in 2025 are projected to be $525 million (+5%), with overseas sales of Furazolidone reaching $366 million (+26%). This growth is primarily driven by the expansion in global markets. However, sales in China are expected to decline by 13% to $100 million [9][21]. - The company is advancing its ATTC platform, with the first molecule A251 entering clinical trials in December 2025. The second molecule A580 is set to start clinical trials in March 2026, and a third candidate A830 is expected to begin Phase 1 trials by the end of 2026. The company plans to seek collaboration opportunities with multinational pharmaceutical companies for its ATTC candidates [2][19]. - The company has adjusted its earnings forecasts for 2026-2027 due to sales adjustments, projecting revenues of $623 million and $745 million for 2026 and 2027, respectively. The net profit is expected to be $53 million and $89 million for the same years [3][21]. Financial Projections - The company forecasts total revenue of $630 million in 2024, decreasing to $549 million in 2025, and then increasing to $623 million in 2026, $745 million in 2027, and $864 million in 2028. The net profit is projected to be $38 million in 2024, significantly increasing to $434 million in 2025, and then decreasing to $53 million in 2026, with a gradual increase to $129 million by 2028 [4][22]. - The company expects a significant increase in cash reserves, with $13.67 billion in cash on hand by the end of 2025 [9]. Market Performance - The closing price of the company's stock is reported at 21.98 HKD, with a market capitalization of 19,174 million HKD. The stock has a 52-week high of 30.75 HKD and a low of 18.36 HKD [5].

Investment Rating - The report maintains a "Buy" rating for Cathay Pacific Airways [6] Core Views - Cathay Pacific Airways reported a revenue of HKD 116.77 billion for 2025, an increase of 11.9% year-on-year, and a net profit attributable to shareholders of HKD 10.83 billion, up 9.5% year-on-year [1] - The company exceeded expectations by HKD 8.6 billion, primarily due to strong passenger performance in the second half of 2025 and non-recurring income of HKD 0.88 billion [1] - The outlook for 2026 is optimistic, with expectations of a significant narrowing of revenue decline due to decreasing supply growth and plans to introduce 25 new aircraft by 2027, increasing fleet capacity by 10.5% [1][5] Summary by Sections Passenger Transport - In the second half of 2025, Cathay Pacific's capacity increased significantly, with ASK/RPK rising by 25.4%/27.9%, reaching 90%/95% of 2019 levels [2] - The passenger load factor improved to 85.6%, up 1.7 percentage points year-on-year, while unit revenue per passenger kilometer saw a reduced decline of 8.2% [2] - Total passenger revenue for the group reached HKD 41.64 billion, a 17.0% increase year-on-year [2] Cargo Transport - Cargo revenue remained stable, with AFTK/RFTK increasing by 8.5%/6.6%, although the load factor decreased by 1.0 percentage points to 58.9% [3] - The overall cargo revenue for the group was HKD 14.81 billion, remaining flat year-on-year [3] Financial Performance - Operating costs for the second half of 2025 were HKD 54.31 billion, up 14.3% year-on-year, but unit non-fuel ATK costs decreased by 2.4% due to improved aircraft utilization [4] - The operating profit margin declined by 0.8 percentage points to 13.7% year-on-year, but net profit attributable to shareholders increased by 15.1% to HKD 7.18 billion [4] - The company announced a total dividend of HKD 0.84 per share, with a payout ratio of 48% [4] Earnings Forecast and Valuation - The forecast for net profit attributable to shareholders for 2026 and 2027 has been raised by 6% and 14% to HKD 9.23 billion and HKD 10.04 billion, respectively [5] - The target price has been adjusted to HKD 17.00, reflecting an increase in valuation to a 2026E PB of 1.8x [5]

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 41.60 [7][5]. Core Views - The company reported a total revenue of USD 3.41 billion for 2025, representing a year-on-year growth of 11.6%, and a net profit of USD 1.22 billion, up 18.9%, exceeding expectations [1][2]. - The ongoing geopolitical tensions in the Middle East are expected to significantly impact global trade supply chains, leading to a potential surge in shipping rates, which could enhance the company's profitability in the short term [1][3]. - The company is well-positioned to benefit from the restructuring of global supply chains, particularly in the Asian market, with a focus on increasing demand for container shipping [4]. Summary by Sections Financial Performance - For 2025, the company achieved a single box revenue of USD 753 per standard container, a 4.5% increase year-on-year, with a total container volume of 3.85 million standard containers, up 7.8% [2]. - The company's gross margin, net margin, and return on equity (ROE) were 38.4%, 35.8%, and 49.3%, respectively, reflecting improvements of 1.0, 2.2, and 6.6 percentage points year-on-year [2]. Market Outlook - The escalation of tensions in the Middle East has increased risks in key maritime routes, leading to shipping companies suspending operations in affected areas, which is expected to drive shipping rates higher [3]. - The supply-demand dynamics in the Asian market are favorable, with demand for small to medium-sized vessels expected to outpace supply growth in the coming years [4]. Earnings Forecast - The earnings forecast for 2026 has been revised upwards, with net profit expectations increased by 14% to USD 1.03 billion, and a new forecast for 2028 set at USD 1.08 billion [5]. - The company maintains a dividend payout ratio assumption of 70% for 2026-2028, reflecting a strong commitment to returning value to shareholders [5].

Investment Rating - The investment rating for Fosun International (00656.HK) is "Buy" (maintained) [1] Core Views - The company is expected to achieve a net loss attributable to shareholders of HKD 215-235 million in 2025, compared to a loss of HKD 43.5 million in the same period of 2024. This is primarily due to significant one-time, concentrated, non-cash impairment charges on certain assets, with real estate-related projects accounting for nearly 55% of the impairments. The company maintains that this does not reflect a change in the fundamental operations of its core business, and the strategic direction remains steadfast [5][6] - The company has set a three-year "billion profit" target, with four core businesses contributing HKD 8 billion, and other insurance companies and joint ventures contributing HKD 4 billion. The investment profit is expected to be around HKD 2 billion, aiming for a net profit target after deducting headquarters and financial expenses [7] Financial Summary and Valuation Metrics - Revenue is projected to decline from HKD 198.2 billion in 2023 to HKD 170.3 billion in 2025, before recovering to HKD 183.9 billion in 2026 and HKD 193.6 billion in 2027, reflecting a year-on-year change of -11.3% in 2025 and +8.0% in 2026 [8] - The net profit is expected to be HKD -21.6 billion in 2025, with a significant year-on-year decline of 395.7%, followed by a recovery to HKD 1.6 billion in 2026 and HKD 1.9 billion in 2027 [8] - The gross margin is forecasted to be 40.8% in 2025, improving to 42.9% in 2026 and 44.1% in 2027 [8] - The company’s price-to-earnings ratio (P/E) is projected to be -1.28 in 2025, 17.0 in 2026, and 14.5 in 2027 [8]

Investment Rating - The report maintains an "Outperform" rating for the company [5][21]. Core Insights - The overseas sales of Furazolidone continue to grow, with a positive revenue guidance for 2026. The total market sales for the company in 2025 are projected to be $525 million (+5%), with overseas sales of Furazolidone reaching $366 million (+26%). This growth is primarily driven by the expansion in global markets. However, sales in China are expected to decline by 13% to $100 million [9][21]. - The company is advancing its ATTC platform, with the first molecule A251 entering clinical trials in December 2025. A580 is set to start clinical trials in March 2026, and a third candidate, A830, is expected to begin Phase 1 trials by the end of 2026. The company plans to seek collaboration opportunities with multinational pharmaceutical companies for its ATTC candidates in 2026 [2][19]. - The report indicates a downward adjustment in the company's earnings forecast for 2026-2027 due to sales adjustments, with new projections for 2028. Expected revenues for 2026-2028 are $623 million, $745 million, and $864 million, respectively. The net profit for 2026-2028 is projected to be $53 million, $89 million, and $129 million, respectively [3][21]. Financial Projections - The company anticipates a significant increase in net profit for 2025, projected at $457 million, largely due to the recognition of a $416 million gain from the sale of a 45% stake in Shanghai Hutchison Pharmaceuticals [9]. - The total revenue for the oncology/immunology business is expected to decline by 21% to $286 million in 2025, primarily due to a decrease in sales of oncology products in the Chinese market [9][21]. - The company expects to have cash on hand of $1.367 billion by the end of 2025 [9]. Clinical Development - The report highlights that the clinical data for the combination of Savolitinib and Tarceva in treating second-line MET amplified EGFR mutation NSCLC is expected to be released in 2026. The SACHI study in China is set to read out data at the ASCO 2025 conference, with domestic approval anticipated in June 2025 [2][19].

Investment Rating - The report maintains a BUY rating on Jacobio with a target price (TP) of HK$10.34, indicating a potential upside of 45.8% from the current price of HK$7.09 [1][2]. Core Insights - Jacobio's JAB-23E73 (pan-KRAS) has shown a highly differentiated safety profile and promising early efficacy, positioning it as a potential first-in-class blockbuster drug with estimated global risk-adjusted peak sales reaching US$2.1 billion [1]. - The company is well-capitalized with a strong financial position, reporting a cash balance of RMB1.13 billion and only RMB95 million in debt as of the end of 2025 [6]. - Jacobio is actively pursuing multiple clinical development catalysts, including a Ph1b/III trial in combination with chemotherapy for 1L PDAC and plans for a pivotal trial in China for 2L PDAC [6]. Financial Summary - Revenue projections show significant growth, with estimates of RMB 782 million for FY26E, followed by RMB 502 million in FY27E and RMB 531 million in FY28E [2][11]. - The net profit is expected to turn positive in FY26E, with an estimated net profit of RMB 487.5 million, followed by RMB 163.6 million in FY27E and RMB 47.7 million in FY28E [2][11]. - R&D expenses are projected to decrease in the coming years, with estimates of RMB 200 million in FY26E, RMB 300 million in FY27E, and RMB 398 million in FY28E [2][11]. Market Performance - Jacobio's market capitalization is approximately HK$5.61 billion, with a 52-week high of HK$11.60 and a low of HK$2.60 [3]. - The stock has shown a 1-month absolute performance of 13.6% and a relative performance of 19.6% [5]. Clinical Development - JAB-23E73 is the first pan-KRAS small molecule drug candidate to enter Ph1 study and release clinical data, demonstrating a significantly better safety profile compared to competitors [6]. - The ongoing Ph1 trial in the US and discussions with AstraZeneca for broader global development plans highlight the company's strategic partnerships and growth potential [6].

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company has released a positive earnings forecast, expecting revenue of RMB 270.0-280.0 billion for 2025, representing a year-on-year growth of 223.3%. Net profit is projected to be RMB 48.0-49.0 billion, with a year-on-year increase of 229.2% [1] - The company is expanding its presence in key domestic markets and has successfully opened its first overseas store in Singapore, indicating strong brand potential for international expansion [2] - The company is innovating its product offerings with new designs and techniques, which have been well received by consumers, showcasing its ability to adapt and grow in the luxury market [3] Financial Summary - For the fiscal year 2025, the company expects to achieve revenue of RMB 27,573 million, a 224% increase from 2024. The net profit is anticipated to be RMB 4,851 million, reflecting a 229% growth [5] - The projected earnings per share (EPS) for 2025 is RMB 27.44, with a price-to-earnings (P/E) ratio of 21.39 [5] - The company’s total assets are expected to grow from RMB 6,337 million in 2024 to RMB 19,690 million in 2025, indicating strong financial health and growth potential [6][7]

Investment Rating - The investment rating for Fosun International (00656.HK) is "Buy" (maintained) [1][5] Core Views - The company is expected to achieve a net loss attributable to shareholders of 215-235 million yuan in 2025, compared to a loss of 43.5 million yuan in the same period of 2024. This is primarily due to significant one-time, concentrated, non-cash impairment provisions on certain assets, with real estate-related projects accounting for nearly 55% of the impairments [5] - Despite the impairments, the company's core business fundamentals remain unchanged, and the strategic direction is firmly established. The company aims to streamline operations and focus on core businesses, which is expected to facilitate future profit release and a more accurate reflection of operational performance [5][6] - The company has set a three-year "100 billion profit" target, with four core businesses contributing 8 billion, other insurance companies and joint ventures contributing 4 billion, and investment profits contributing about 2 billion. After deducting headquarters and financial expenses, the net profit target is achievable [7] Financial Summary and Valuation Indicators - Revenue projections for 2025 are estimated at 170.34 billion yuan, with a year-over-year decline of 11.3%. The net profit for 2025 is projected at -21.56 billion yuan, reflecting a significant year-over-year decrease of 395.7% [8] - The gross margin is expected to be 40.8% in 2025, with a net margin of -12.7%. The return on equity (ROE) is projected at -12.5% for the same year [8] - The earnings per share (EPS) for 2025 is forecasted to be -2.6 yuan, with a price-to-earnings (P/E) ratio of -1.28 for 2025, and 17 and 14.5 for 2026 and 2027, respectively [8]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [5][7]. Core Insights - The company focuses on the research and development of innovative drugs for autoimmune diseases and has established strategic partnerships with various pharmaceutical companies, indicating strong potential for future product sales and continued pipeline licensing opportunities [2][5]. - The company has a comprehensive pipeline targeting four major autoimmune diseases, with a priority on skin diseases, currently holding one approved product, nine in development, and over twenty IND approved projects [5][7]. - The global autoimmune drug market is projected to reach USD 176.7 billion by 2030, with biologics' market share expected to increase from 72.8% in 2022 to 82.1% by 2030 [5][7]. Financial Summary - Revenue projections for the company are as follows: - 2024: RMB 159 million - 2025: RMB 687 million (up 333%) - 2026: RMB 594 million (down 14%) - 2027: RMB 755 million (up 27%) [6][8]. - The company is expected to achieve EPS of RMB 0.61, 0.42, and 0.83 for the years 2025, 2026, and 2027 respectively [5][7]. - The target price is set at HKD 30.15 based on DCF valuation methods [5][7]. Business Segmentation - The company's core business revenue is divided into three segments: - Revenue from licensing agreements - Research and development services - Drug sales - Forecasted revenue breakdown for 2024-2027 indicates significant growth in licensing income, with a projected increase from RMB 100.94 million in 2024 to RMB 560 million in 2027 [8].

Investment Rating - The report maintains an "Outperform" rating for the company [2][4][14]. Core Insights - The company achieved a revenue of 8.321 billion yuan this quarter, representing a year-on-year growth of 8%. The breakdown includes: 1) Value-added services revenue of 3.3 billion yuan, up 6% year-on-year, with over 25.3 million premium members, reflecting a 13% increase; 2) Advertising revenue of 3 billion yuan, up 27% year-on-year, driven by the release of potential advertising inventory and significant growth in various advertising formats; 3) Game revenue of 1.5 billion yuan, down 14% year-on-year, primarily due to a high base from the previous year; 4) IP derivatives and other income of 480 million yuan, up 3% year-on-year [1][6][7]. - The adjusted net profit for the company was 880 million yuan, with an adjusted net profit margin of 11%, an increase of 5 percentage points compared to the same period last year. The adjusted operating profit was 840 million yuan, with an adjusted operating profit margin rising from 6% to 10% [7][14]. Financial Forecasts - Revenue projections for 2026 and 2027 have been adjusted to 33.7 billion yuan and 37.3 billion yuan, respectively, reflecting increases of 3.2% and 2.2%. An additional revenue forecast for 2028 is set at 41.2 billion yuan. Adjusted net profit estimates for 2026 and 2027 are 3.3 billion yuan and 4.2 billion yuan, with adjustments of -3% and -8% due to increased investments in AI [2][14][19]. - The company’s projected PE ratio for 2026 is approximately 24x, indicating a favorable valuation relative to its earnings growth [2][14]. Operational Data - The company reported a daily active user (DAU) count of 113 million, an increase of 10% year-on-year, and a monthly active user (MAU) count of 366 million, up 8% year-on-year. The average user engagement time was 107 minutes, also reflecting an 8% year-on-year increase [7][14]. - The company has repurchased 14.7 million USD worth of shares this quarter, with a total repurchase amount of 131 million USD since November 2024, leaving approximately 70 million USD remaining in the repurchase program [2][7].